Cargando…
Immunogenicity Risk Profile of Nanobodies
Nanobodies (Nbs), the variable domains of camelid heavy chain-only antibodies, are a promising class of therapeutics or in vivo imaging reagents entering the clinic. They possess unique characteristics, including a minimal size, providing fast pharmacokinetics, high-target specificity, and an affini...
Autores principales: | Ackaert, Chloé, Smiejkowska, Natalia, Xavier, Catarina, Sterckx, Yann G. J., Denies, Sofie, Stijlemans, Benoit, Elkrim, Yvon, Devoogdt, Nick, Caveliers, Vicky, Lahoutte, Tony, Muyldermans, Serge, Breckpot, Karine, Keyaerts, Marleen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985456/ https://www.ncbi.nlm.nih.gov/pubmed/33767701 http://dx.doi.org/10.3389/fimmu.2021.632687 |
Ejemplares similares
-
Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer
por: D’Huyvetter, Matthias, et al.
Publicado: (2014) -
Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide–Cysteine Chemistry
por: Chigoho, Dora Mugoli, et al.
Publicado: (2021) -
Targeted Radionuclide Therapy with A (177)Lu-labeled Anti-HER2 Nanobody
por: D'Huyvetter, Matthias, et al.
Publicado: (2014) -
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle
por: Dekempeneer, Yana, et al.
Publicado: (2016) -
Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33
por: Romão, Ema, et al.
Publicado: (2020)